De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Oragenics Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Mike Redmond

Algemeen directeur

US$343.8k

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	9yrs

Recente managementupdates

Recent updates

CEO

Mike Redmond (63 yo)

less than a year

Tenure

US$343,800

Compensatie

Mr. Joseph Michael Redmond, also known as Mike, serves as President of Oragenics, Inc. since December 28, 2023 and also serves as its Interim Principal Executive Officer since February 12, 2024 and served...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Charles Pope	Executive Chairman	14.3yrs	US$196.75k	0.29% $ 8.3k
Joseph Redmond	President & Interim Principal Executive Officer	less than a year	US$343.80k	geen gegevens
Janet Huffman	CFO, Secretary & Treasurer	1.6yrs	US$365.40k	0.17% $ 4.9k
James Kelly	Chief Medical Officer & Member of Scientific Advisor	less than a year	geen gegevens	geen gegevens
William Peacock	Chief Clinical Officer	less than a year	geen gegevens	geen gegevens

0.7yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 0A64 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.7 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Charles Pope	Executive Chairman	14.3yrs	US$196.75k	0.29% $ 8.3k
James Kelly	Chief Medical Officer & Member of Scientific Advisor	less than a year	geen gegevens	geen gegevens
John Gandolfo	Independent Director	less than a year	US$25.13k	0% $ 0
Frederick Telling	Independent Director	14.3yrs	US$156.75k	0.43% $ 12.2k
Alan Dunton	Independent Director	13.5yrs	US$140.50k	0.30% $ 8.4k
Bruce Cassidy	Independent Director	less than a year	US$25.13k	4.1% $ 115.6k
Robert Koski	Independent Director	15.3yrs	US$134.25k	0.32% $ 9.1k
Kimberly Murphy	Director	4.4yrs	US$592.15k	0.29% $ 8.1k
Timothy Cooke	Member of Scientific Advisor	no data	geen gegevens	geen gegevens
David Zarley	Member of Scientific Advisor	no data	geen gegevens	geen gegevens
Terrence Cochrane	Member of Scientific Advisor	no data	geen gegevens	geen gegevens

9.0yrs

Gemiddelde duur

70yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 0A64 wordt beschouwd als ervaren (gemiddelde ambtstermijn 9 jaar).

Oragenics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Oragenics, Inc. Appoints William “Frank” Peacock MD as Chief Clinical Officer

Oragenics Appoints James Kelly MD as Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Oragenics, Inc. Announces CEO Changes

Oragenics, Inc., Annual General Meeting, Dec 14, 2023

Oragenics Announces Directorate Appointments

Insufficient new directors

Recent updates

Oragenics, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Oragenics, Inc. Plans to Initiate Phase II Clinical Trials

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

Oragenics, Inc. has completed a Follow-on Equity Offering in the amount of $4.453593 million.

Oragenics, Inc. has filed a Follow-on Equity Offering in the amount of $4.453593 million.

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients

Oragenics, Inc. has filed a Follow-on Equity Offering.

Oragenics, Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

First half 2024 earnings released: US$1.21 loss per share (vs US$2.92 loss in 1H 2023)

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

Oragenics Improves Intranasal Drug Formulation for Treating Concussed Patients

Oragenics, Inc. has completed a Follow-on Equity Offering.

Oragenics, Inc. has filed a Follow-on Equity Offering.

Oragenics Announces NYSE American Acceptance of Plan of Compliance

Oragenics Announces NYSE American Acceptance of Plan of Compliance

Oragenics, Inc. Appoints William “Frank” Peacock MD as Chief Clinical Officer

Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial

First quarter 2024 earnings released: US$0.70 loss per share (vs US$1.41 loss in 1Q 2023)

Full year 2023 earnings released: US$9.18 loss per share (vs US$7.11 loss in FY 2022)

Oragenics Appoints James Kelly MD as Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

Oragenics, Inc. has completed a Follow-on Equity Offering in the amount of $2.1 million.

Oragenics, Inc. has filed a Follow-on Equity Offering.

Oragenics, Inc. Announces CEO Changes

Oragenics, Inc. Prepares for Phase II Clinical Trials to Treat Concussion

New major risk - Market cap size

Oragenics, Inc. has completed a Follow-on Equity Offering in the amount of $5 million.

New major risk - Shareholder dilution

Oragenics, Inc. has filed a Follow-on Equity Offering.

Oragenics, Inc. (NYSEAM:OGEN) completed the acquisition of Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.

Third quarter 2023 earnings released: US$0.85 loss per share (vs US$1.99 loss in 3Q 2022)

Oragenics, Inc., Annual General Meeting, Dec 14, 2023

Oragenics Announces Directorate Appointments

Oragenics, Inc. (NYSEAM:OGEN) entered into an Asset Purchase Agreement to acquire Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.

Insufficient new directors

Second quarter 2023 earnings released: US$1.51 loss per share (vs US$1.85 loss in 2Q 2022)

Oragenics, Inc. announced that it has received $0.85 million in funding

Insufficient new directors

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd